Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in NRT?
Novogen: THE INVESTMENT CASE

Novogen: Access latest PPT from Proactive's CEO Sessions

Dr James Garner talked clinical-stage programs with investors.
Novogen: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: NRT The Big Picture
Dr James Garner, chief executive officer, Novogen

Novogen’s (ASX:NRT, NASDAQ:NVGN) chief executive officer, Dr James Garner, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April.

Novogen is an emerging oncology drug developer with two clinical-stage programs.

The company's value proposition is to partner with big pharma for late-stage development to bring to market.

ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future NRT Company articles
View full NRT profile View Profile

Novogen Timeline

Newswire
August 05 2015

Related Articles

Netscientific has its thumbs in a few clinical pies
April 01 2017
The firm commercialises intellectual property (IP) through developing early and mid-stage healthcare firms
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug
genomics.jpg
October 05 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use